Tokyo Tape
Sign in
← Falco Holdings

Quarterly report · Q3

4671.TEDINET S100Q645
Period2022-04-01 → 2022-12-31
Filed2023-02-10
StandardJapan GAAP
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 36
MetricValuePeriodScopeSource row
Revenue¥35.9bn2022-04-01 → 2022-12-31Cons.Net sales
Revenue¥50.0bn2021-04-01 → 2022-03-31Cons.Net sales (5-year summary)
Revenue¥36.4bn2021-04-01 → 2021-12-31Cons.Net sales
Operating income¥2.5bn2022-04-01 → 2022-12-31Cons.Operating income
Operating income¥3.8bn2021-04-01 → 2021-12-31Cons.Operating income
Ordinary income¥2.7bn2022-04-01 → 2022-12-31Cons.Ordinary income
Ordinary income¥5.8bn2021-04-01 → 2022-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥4.1bn2021-04-01 → 2021-12-31Cons.Ordinary income
Profit before tax¥2.7bn2022-04-01 → 2022-12-31Cons.Income before income taxes
Profit before tax¥4.0bn2021-04-01 → 2021-12-31Cons.Income before income taxes
Net income (owners)¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss attributable to owners of parent
Net income (owners)¥3.5bn2021-04-01 → 2022-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss attributable to owners of parent
Net income¥1.5bn2022-04-01 → 2022-12-31Cons.Profit loss
Net income¥2.5bn2021-04-01 → 2021-12-31Cons.Profit loss
Total assets¥38.3bnat 2022-12-31Cons.Assets
Total assets¥40.3bnat 2022-03-31Cons.Assets
Total assets¥38.7bnat 2021-12-31Cons.Total assets (5-year summary)
Total liabilities¥13.6bnat 2022-12-31Cons.Liabilities
Total liabilities¥16.8bnat 2022-03-31Cons.Liabilities
Net assets / equity¥24.7bnat 2022-12-31Cons.Net assets
Net assets / equity¥23.5bnat 2022-03-31Cons.Net assets
Net assets / equity¥22.4bnat 2021-12-31Cons.Net assets (5-year summary)
Cash and deposits¥10.0bnat 2022-12-31Cons.Cash and deposits
Cash and deposits¥10.6bnat 2022-03-31Cons.Cash and deposits
EPS (basic)¥146.882022-04-01 → 2022-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥39.432022-10-01 → 2022-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (basic)¥3392021-04-01 → 2022-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥242.322021-04-01 → 2021-12-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥38.082021-10-01 → 2021-12-31dCons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥146.232022-04-01 → 2022-12-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥336.992021-04-01 → 2022-03-31Cons.Diluted earnings per share (5-year summary)
EPS (diluted)¥241.232021-04-01 → 2021-12-31Cons.Diluted earnings per share (5-year summary)
Equity ratio64.2%at 2022-12-31Cons.Equity to asset ratio (5-year summary)
Equity ratio58.1%at 2022-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio57.6%at 2021-12-31Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingrevenue intersegment2022-04-01 → 2022-12-31−¥6m
Reconciling Itemsreconcilingsegment profit2022-04-01 → 2022-12-31−¥362m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥23.9bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥5m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥2.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2022-04-01 → 2022-12-31¥12.0bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2022-04-01 → 2022-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2022-04-01 → 2022-12-31¥590m
—segment totalrevenue2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue external2022-04-01 → 2022-12-31¥35.9bn
—segment totalrevenue intersegment2022-04-01 → 2022-12-31¥6m
—segment totalsegment profit2022-04-01 → 2022-12-31¥2.9bn
Reconciling Itemsreconcilingrevenue2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingrevenue intersegment2021-04-01 → 2021-12-31−¥12m
Reconciling Itemsreconcilingsegment profit2021-04-01 → 2021-12-31−¥279m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥24.2bn
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥11m
jpcrp040300-q3r_E04982-000Clinical Testing Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥3.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue external2021-04-01 → 2021-12-31¥12.3bn
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentrevenue intersegment2021-04-01 → 2021-12-31¥0
jpcrp040300-q3r_E04982-000Dispensing Pharmacy Businessreportable segmentsegment profit2021-04-01 → 2021-12-31¥770m
—segment totalrevenue2021-04-01 → 2021-12-31¥36.5bn
—segment totalrevenue external2021-04-01 → 2021-12-31¥36.4bn
—segment totalrevenue intersegment2021-04-01 → 2021-12-31¥12m
—segment totalsegment profit2021-04-01 → 2021-12-31¥4.1bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 355
ItemContextValueUnit
Retirement benefit expenses elPrior1YTDDuration77000000JPY
Retirement benefit expenses elCurrentYTDDuration－JPY
Extraordinary lossPrior1YTDDuration99000000JPY
Extraordinary lossCurrentYTDDuration134000000JPY
Income before income taxesPrior1YTDDuration3994000000JPY
Income before income taxesCurrentYTDDuration2701000000JPY
Income taxes currentPrior1YTDDuration1496000000JPY
Income taxes currentCurrentYTDDuration1098000000JPY
Income taxes deferredPrior1YTDDuration-26000000JPY
Income taxes deferredCurrentYTDDuration62000000JPY
Income taxesPrior1YTDDuration1470000000JPY
Income taxesCurrentYTDDuration1160000000JPY
Profit lossPrior1YTDDuration2523000000JPY
Profit lossCurrentYTDDuration1540000000JPY
Profit loss attributable to owners of parentPrior1YTDDuration2523000000JPY
Profit loss attributable to owners of parentCurrentYTDDuration1540000000JPY
Profit lossPrior1YTDDuration2523000000JPY
Profit lossCurrentYTDDuration1540000000JPY
Valuation difference on available for sale securities net of tax ociPrior1YTDDuration-112000000JPY
Valuation difference on available for sale securities net of tax ociCurrentYTDDuration282000000JPY
Other comprehensive incomePrior1YTDDuration-112000000JPY
Other comprehensive incomeCurrentYTDDuration282000000JPY
Comprehensive incomePrior1YTDDuration2411000000JPY
Comprehensive incomeCurrentYTDDuration1823000000JPY
Comprehensive income attributable to owners of the parentPrior1YTDDuration2411000000JPY
Comprehensive income attributable to owners of the parentCurrentYTDDuration1823000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember24171000000JPY
Revenues from external customersPrior1YTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember12269000000JPY
Revenues from external customersPrior1YTDDuration_ReportableSegmentsMember36441000000JPY
Revenues from external customersPrior1YTDDuration_ReconcilingItemsMember－JPY
Revenues from external customersPrior1YTDDuration36441000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember11000000JPY
Transactions with other segmentsPrior1YTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember0JPY
Transactions with other segmentsPrior1YTDDuration_ReportableSegmentsMember12000000JPY
Transactions with other segmentsPrior1YTDDuration_ReconcilingItemsMember-12000000JPY
Transactions with other segmentsPrior1YTDDuration－JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember24182000000JPY
Net salesPrior1YTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember12270000000JPY
Net salesPrior1YTDDuration_ReportableSegmentsMember36453000000JPY
Net salesPrior1YTDDuration_ReconcilingItemsMember-12000000JPY
Net salesPrior1YTDDuration36441000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember3303000000JPY
Operating incomePrior1YTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember770000000JPY
Operating incomePrior1YTDDuration_ReportableSegmentsMember4074000000JPY
Operating incomePrior1YTDDuration_ReconcilingItemsMember-279000000JPY
Operating incomePrior1YTDDuration3794000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E04982-000ClinicalTestingBusinessReportableSegmentsMember23892000000JPY
Revenues from external customersCurrentYTDDuration_jpcrp040300-q3r_E04982-000DispensingPharmacyBusinessReportableSegmentsMember11985000000JPY
Revenues from external customersCurrentYTDDuration_ReportableSegmentsMember35878000000JPY
Revenues from external customersCurrentYTDDuration_ReconcilingItemsMember－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2022-03-31pass
balance sheet identityconsolidated 2022-12-31pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2022-03-31pass
statement vs summary · net assetsconsolidated 2022-12-31pass
statement vs summary · net income attributable to parentconsolidated 2021-04-01/2021-12-31pass
statement vs summary · net income attributable to parentconsolidated 2022-04-01/2022-12-31pass
statement vs summary · revenueconsolidated 2021-04-01/2021-12-31pass
statement vs summary · revenueconsolidated 2022-04-01/2022-12-31pass
statement vs summary · total assetsconsolidated 2022-03-31pass
statement vs summary · total assetsconsolidated 2022-12-31pass